Protagonist Therapeutics Inc [PTGX] stock is trading at $67.04, up 2.66%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The PTGX shares have gain 3.17% over the last week, with a monthly amount glided 16.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Protagonist Therapeutics Inc [NASDAQ: PTGX] stock has seen the most recent analyst activity on September 17, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $72. Previously, Leerink Partners started tracking the stock with Outperform rating on September 12, 2025, and set its price target to $73. On June 17, 2025, Citigroup initiated with a Buy rating and assigned a price target of $72 on the stock. Goldman started tracking the stock assigning a Neutral rating and suggested a price target of $47 on December 06, 2024. BMO Capital Markets initiated its recommendation with an Outperform and recommended $62 as its price target on December 06, 2024. Wedbush started tracking with an Outperform rating for this stock on November 05, 2024, and assigned it a price target of $58. In a note dated September 24, 2024, TD Cowen initiated an Buy rating and provided a target price of $65 on this stock.
Protagonist Therapeutics Inc [PTGX] stock has fluctuated between $33.31 and $68.26 over the past year. Currently, Wall Street analysts expect the stock to reach $73 within the next 12 months. Protagonist Therapeutics Inc [NASDAQ: PTGX] shares were valued at $67.04 at the most recent close of the market. An investor can expect a potential return of 8.89% based on the average PTGX price forecast.
Analyzing the PTGX fundamentals
Protagonist Therapeutics Inc [NASDAQ:PTGX] reported sales of 209.18M for the trailing twelve months, which represents a growth of 33.09%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.12%, Pretax Profit Margin comes in at 0.26%, and Net Profit Margin reading is 0.26%. To continue investigating profitability, this company’s Return on Assets is posted at 0.07, Equity is 0.08 and Total Capital is 0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 65.88 points at the first support level, and at 64.71 for the second support level. However, for the 1st resistance point, the stock is sitting at 67.89, and for the 2nd resistance point, it is at 68.73.
Ratios To Look Out For
For context, Protagonist Therapeutics Inc’s Current Ratio is 16.97. Further, the Quick Ratio stands at 16.97, while the Cash Ratio is 4.75. Considering the valuation of this stock, the price to sales ratio is 19.94, the price to book ratio is 6.23 and price to earnings (TTM) ratio is 94.08.
Transactions by insiders
Recent insider trading involved Waddill William D., Director, that happened on Sep 22 ’25 when 4000.0 shares were sold. Director, WILLIAM WADDILL completed a deal on Sep 22 ’25 to buy 4000.0 shares. Meanwhile, Director Waddill William D. sold 4000.0 shares on Aug 27 ’25.
